EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Physiomics Plc (PYC) fair value: what the stock is really worth

We calculate from audited financials what Physiomics Plc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 25, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · ISIN GB00BDR6W943

PP Thin data Jun 25, 2026

Physiomics Plc

PYC · LSE

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value £0.0085 · Strongly undervalued (+62%)
!Quality 43/100
!Weak Growth (revenue 5y −0.4 %/yr)
!Loss-making · -48.1% net margin (TTM)
!negative free cash flow
!Mixed vs. peers (4/9)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Physiomics Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.0705 £0.0027 Fair Value £0.0085 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 25, 2026.

How to read this chart

60‑month range £0.0027 – £0.0705 · the £0.0053 price screens below the £0.0085 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 25, 2026.

Follow Physiomics in your weekly email

Every Wednesday you see whether Physiomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.

Show more

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.

Stock analysis

Physiomics Plc (PYC) currently trades at £0.0053, while our model-based Fair Value estimate is £0.0085, implying the stock looks roughly 38.2% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Physiomics Plc reported revenue of £784K in FY2025 versus £702K in FY2021, a compound +2.8%/yr. Reported net income was −£415K in FY2025.

Key figures

Market cap 2.5M GBX · P/S ratio 2.47 · Net margin −53.0% · Return on equity −120% · Return on assets (EBIT) −70.6% · Operating margin −61.9% · Revenue (TTM) £1.0M · Revenue growth (YoY) +49.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 62%, PYC screens cheaper than that median.

Notify me when PYC reaches fair value

Put PYC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 44 · Market factors (momentum, volatility) 46

Profitability 13
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 29
Calm price path (market factor)
Momentum 53
Price trend over the last 3–12 months (market factor)
52W Momentum 51
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+44.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−22.2% (2020) → −58.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PYC, get fair value alerts →

Compare Physiomics Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside +62% · Top 25%
Profitability
Return on assets −62% · Bottom 25%
Net margin (TTM) −48% · Bottom 25%
Operating margin (TTM) −62% · Bottom 25%
Growth and dividend
Revenue growth 49% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.77× · Priciest 25%
P/S (TTM) 3.28× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Physiomics Plc · Fair Value
£0.0085 +38%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Physiomics Plc Fair Value". https://www.fairvalue-calculator.com/stock/PYC

Frequently asked questions

Is Physiomics Plc (PYC) overvalued or undervalued?
As of Jun 25, 2026, our model estimates a fair value of £0.0085 versus a price of £0.0053, about +62% upside (undervalued).
What is the fair value of PYC?
Our model-based fair value for Physiomics Plc is £0.0085 (as of Jun 25, 2026), built from audited fundamentals. The current price: £0.0053.
What is the quality score of PYC?
Physiomics Plc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Physiomics Plc (PYC)?
Our model-based price target is the fair value of £0.0085 (as of Jun 25, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Physiomics Plc stock forecast for 2026?
Our models put fair value at £0.0085, about +62% upside versus a price of £0.0053 (undervalued). The calculation is refreshed regularly with new filings.
What is the revenue of Physiomics Plc (PYC)?
Physiomics Plc reported trailing-twelve-month revenue of about £1.0M (latest available figure, as of Jun 25, 2026).
What is the intrinsic value of Physiomics Plc (PYC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Physiomics Plc it is £0.0085 per share (as of Jun 25, 2026), against a price of £0.0053. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Physiomics Plc stock overvalued or undervalued in 2026?
As of Jun 25, 2026, PYC trades below its calculated fair value: price £0.0053, fair value £0.0085, a gap of about +62% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PYC?
No. The price is what the market pays today (£0.0053); the fair value is what the company's own numbers justify (£0.0085). For Physiomics Plc the two are £0.0033 per share apart. That gap is exactly why we show both numbers side by side.
How much is Physiomics Plc worth?
The market values Physiomics Plc at about 2.5M GBX (market capitalisation, as of Jun 25, 2026). Per share that is £0.0053; our models calculate a fair value of £0.0085 per share.
How solid is the balance sheet of Physiomics Plc (PYC)?
Balance-sheet figures for Physiomics Plc (as of Jun 25, 2026): return on equity −119.7%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is PYC from its 52-week high?
Physiomics Plc trades at £0.0053, about 25% below its 52-week high of £0.0070 and 98% above the low of £0.0027 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0085 is for.
Which stocks are comparable to Physiomics Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Physiomics Plc stock attractive at the current price?
The data as of Jun 25, 2026: price £0.0053, calculated fair value £0.0085 (+62%), Quality Score 43/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PYC calculated?
We run Physiomics Plc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0085, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Physiomics Plc currently trades 62 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Physiomics Plc (PYC)?
The closing price on Sep 23, 2026 was £0.0053. Our model-based fair value is £0.0085, about +62% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Physiomics Plc right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (£0.0085). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Physiomics Plc

How large is the market capitalisation of Physiomics Plc (PYC)?
The market capitalisation of Physiomics Plc is 2.5M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Physiomics Plc (PYC)?
The price-to-sales ratio of Physiomics Plc is 2.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Physiomics Plc (PYC)?
The net margin of Physiomics Plc is −53.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Physiomics Plc (PYC)?
The return on equity (ROE) of Physiomics Plc is −120% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Physiomics Plc (PYC)?
On an EBIT basis the return on assets of Physiomics Plc is −70.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Physiomics Plc (PYC)?
The operating margin of Physiomics Plc is −61.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Physiomics Plc (PYC)?
Revenue at Physiomics Plc is growing +49.2% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Physiomics Plc (PYC) generate?
The free cash flow of Physiomics Plc is −550K GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Physiomics Plc (PYC) hold?
Physiomics Plc holds more cash than debt, 461K GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Physiomics Plc in the live analysis

One click puts Physiomics Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.